# Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles

> **NCT03878758** · NA · COMPLETED · sponsor: **Becton, Dickinson and Company** · enrollment: 158 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DEVICE:** BD Nano™ PRO
- **DEVICE:** 33G Artsana Insupen Extr3me
- **DEVICE:** 34G Artsana Insupen Extr3me
- **DEVICE:** Simple Diagnostics Comfort EZ™

## Key facts

- **NCT ID:** NCT03878758
- **Lead sponsor:** Becton, Dickinson and Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-07
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2020-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878758, "Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT03878758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*